Get started
Work

A Risk Adapted Approach Utilizing Plerixafor In Autologous Peripheral Blood Stem Cell Mobilization

Year: 2010
Type: article
Abstract: Many patients (pts) who are eligible for ASCT are unable to collect a minimum number of CD34 + stem cells to support high dose chemotherapy and ASCT. Plerixafor, a CXCR4 antagonist, in combination with G-CSF mobilizes more CD34+ stem cells when compared to G-CSF alone. Due to its cost, we commenced a risk adapted approach to the utilization of plerixafor for stem cell mobilization in pts undergoing ASCT. Our goal was to add plerixafor in pts who had ineffective mobilization thereby preventing mobilization failures.
DOI: 10.1016/j.bbmt.2009.12.141
Authors: I.N. Micallef, D.J. Inwards, A. Dispenzieri, D.A. Gastineau, M.A. Gertz, S. Hayman, W.J. Hogan, P.B. Johnston, S. Kumar, M. Lacy, M.R. Litzow, L.E. Porrata, F. Buadi, S.M. Ansell, D. Dingli, R. Wolf, T. Miceli, J.L. Winters
Institution: Mayo Clinic
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2093701453
FWCI: 1.078
Cites:
Cited by: 14
Related to: 10